skip to main content

Prostate Cancer

AACR 2024: NextGen Star Abhijit Parolia presents on new protein that drives prostate cancer progression

Abhijit Parolia, M.S., Ph.D., assistant professor of pathology and urology at the University of Michigan Health Rogel Cancer Center, was named at NextGen Star by the American Association of Cancer Research.

AACR 2024: Chinnaiyan presents on possible therapies to target oncogenic transcription factors

Arul Chinnaiyan, M.D., Ph.D., was one of several Rogel researchers to present at the American Association for Cancer Research 2024 Annual Meeting.

Pluvicto treatment gives prostate cancer patient another chance

After multiple rounds of treatments for his metastatic castration resistant prostate cancer, Donald Reynolds learned there were no more treatment options. Then he learned about a research study at the Rogel Cancer Center for Pluvicto, a radioactive drug treatment for metastatic castration resistant prostate cancer.

New advances may lead to prostate cancer treatment with fewer side effects

Within the last few years, nuclear medicine has added to cutting edge treatment options for cancer. One of the latest advancements is the use of a treatment called Pluvicto to treat metastatic castration-resistant prostate cancer.

Rogel researcher gets $1.1M specialized grant to understand the biology of low-risk prostate cancer

For men with a type of low-risk early prostate cancer, surveillance can be an option over immediate treatment. To help providers and patients make more informed decisions about safely choosing surveillance, Rogel Cancer Center researcher Simpa Salami, M.D., M.P.H., received a $1.14 million grant from the National Cancer Institute to answer lingering questions about the biology of these early prostate cancers.

Free online tool helps prostate cancer patients save on drug costs

A free online tool could potentially save some prostate cancer patients more than $9,000 in out-of-pocket drug costs, a study finds. For patients enrolled in Medicare Part D prescription drug plans, out of pocket costs can vary significantly.

New approach targeting deadly form of prostate cancer shows promise

Using tissue samples and cell models from patients, Joshi Alumkal, M.D., Wicha Family Professor of Oncology and leader of the genitourinary medical oncology section at Rogel, and his team zeroed in on the lysine specific demethylase 1, a protein involved in turning genes off and on in normal and cancer cells that appears particularly important in certain aggressive forms of prostate cancer.

Rogel researchers receive $4M through Prostate Cancer Foundation’s inaugural TACTICAL awards program

Principal investigator Arul Chinnaiyan, M.D., Ph.D., will lead a $4 million project that will employ a suite of cutting-edge drug development techniques to develop an effective inhibitor of MYC, a major driver of about 70% of all cancers, including prostate cancer.

Lower prostate cancer screening rates associated with subsequent increase in advanced cancers

In the face of conflicting evidence over the risks and benefits of routine prostate cancer screenings, a large, longitudinal analysis found Veterans Health Administration (VA) medical centers with lower prostate screening rates had higher rates of metastatic prostate cancer cases in subsequent years than centers with higher screening rates.

Some prostate treatments may rewire the tumors, research suggests

Drugs like enzalutamide that inhibit male hormones from activating the androgen receptor have been used to treat advanced prostate cancer for more than a decade. While successful in most cases, these drugs can eventually stop working, but there is a limited understanding about how this change occurs.